Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02167945 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 615
- Enrollment target
NCT02167945 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 615 participants.
The verdict
NCT02167945, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 615 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the effect of treatment with ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333; 3-DAA regimen, with or without ribavirin (RBV) in adults with chronic hepatitis C virus genotype 1 (HCV GT1) infection.
Interventions
- DRUG Ribavirin (RBV)
- DRUG ABT-333
- DRUG ABT-450/r/ABT-267
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 615 participants |
| Start Date | 2014-06-12 |
| Est. Completion | 2021-05-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02167945
The ClinicalTrials.gov registry entry for NCT02167945 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 615 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin (RBV) is the first listed.
NCT02167945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02167945 about?
NCT02167945 is a clinical study titled "A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection". The purpose of this study was to evaluate the effect of treatment with ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333; 3-DAA regimen, with or without ribavirin (RBV) in adults with chronic hepatitis C virus genotype 1 (HCV GT1) infection.
What is the current status of trial NCT02167945?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 615 participants. The study started on 2014-06-12. Estimated completion is 2021-05-13.
What interventions are being tested in trial NCT02167945?
The interventions under investigation include: Ribavirin (RBV) (DRUG), ABT-333 (DRUG), ABT-450/r/ABT-267 (DRUG).
Who is sponsoring clinical trial NCT02167945?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.